Real-World Clinical Experience of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Olaparib + Abiraterone (PROceed)

Trial Identifier: D0817R00074
Sponsor: AstraZeneca
Collaborator:
Merck Sharp & Dohme LLC
Start Date: February 2024
Primary Completion Date: January 2027
Study Completion Date: January 2027
Condition: Prostate Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Germany Aschaffenburg, Germany
Germany Augsburg, Germany
Germany Bergisch Gladbach, Germany
Germany Berlin, Germany
Germany Bonn, Germany
Germany Dresden, Germany
Germany Duisburg, Germany
Germany Eisenach, Germany
Germany Frankfurt, Germany
Germany Greifswald, Germany
Germany Halle (Saale), Germany
Germany Hamburg, Germany
Germany Hannover, Germany
Germany Heidelberg, Germany
Germany Heinsberg, Germany
Germany Herzogenaurach, Germany
Germany Koln, Germany
Germany Leipzig, Germany
Germany Luebeck, Germany
Germany Luneburg, Germany
Germany Lutherstadt Eisleben, Germany
Germany M nster, Germany
Germany Magdeburg, Germany
Germany Marburg, Germany
Germany Muelheim, Germany
Germany N rnberg, Germany
Germany Neunkirchen, Germany
Germany Ruesselsheim, Germany
Germany Saalfeld, Germany
Germany Speyer, Germany
Germany Trier, Germany
Germany Tuebingen, Germany
Germany Westerstede, Germany
Germany Wetzlar, Germany